PharmacoEconomics

, Volume 5, Issue 6, pp 453–459 | Cite as

Alglucerase for Gaucher’s Disease

Dose, Costs and Benefits
  • Ernest Beutler
  • Alan M. Garber
Guest Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: in vivo c1earance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15: 269–278, 1978PubMedCrossRefGoogle Scholar
  2. Barton NW, Brady R, Dambrosia JM. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1564–1565, 1993PubMedCrossRefGoogle Scholar
  3. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher’s di sease. New England Journal of Medicine 324: 1464–1410, 1991aPubMedCrossRefGoogle Scholar
  4. Barton NW, Brady RO, Murray GJ, et al. Enzyme-replacement therapy for Gaucher’s disease: reply. New England Journal of Medicine 325: 1811, 1991bCrossRefGoogle Scholar
  5. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 87: 1913–1916, 1990PubMedCrossRefGoogle Scholar
  6. Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256: 794–199, 1992PubMedCrossRefGoogle Scholar
  7. Beutler E, Dale GL, Guinto E, Kuhl W. Enzyme replacement therapy in Gaucher’s disease: preliminary clinical lrial of a new enzyme preparation. Proceedings of the National Academy of Sciences of the United States of America 74: 4620–4623, 1977PubMedCrossRefGoogle Scholar
  8. Beutler E, Figueroa M, Koziol J. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1567, 1993aGoogle Scholar
  9. Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. British Journal of Haematology, in press, 1993Google Scholar
  10. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. American Journal of Human Genetics 52: 85–88, 1993bPubMedGoogle Scholar
  11. Beutler E, Kay A, Saven A. et al. Enzyme replacement therapy for Gaucher disease. Blood 78: 1183–1189, 1991PubMedGoogle Scholar
  12. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. New England Journal of Medicine 291: 989–993, 1974Google Scholar
  13. Culbertson VL, Rhodes RS, Hill EP, Rhodes PJ. Impact of home infusion therapy on the Colorado Medicaid program budget. American Journal of Hospital Pharmacy 45: 1346–1349, 1988PubMedGoogle Scholar
  14. De Duve C. From cytases to Iysosomes. Federal Proceedings 23: 1045–1049, 1964Google Scholar
  15. Doebber TW, Wu MS, Bugianesi RL, ct al. Enhanced macrophage uptake of synthetieally glycosylated human placental beta-glucocerebrosidase. Journal of Biological Chemistry 257: 2193–2199, 1982PubMedGoogle Scholar
  16. Eto Y, Kawame H, Hasegawa Y, Ohashi T, Ida H, et al. Molecular characteristics in Japanese patients with lipidosis: novel mutations in metachromatic leukodystrophy and Gaucher disease. Molecular and Cellular Biochemistry 119: 179–184, 1993PubMedCrossRefGoogle Scholar
  17. Fallet S, Sibille A, Mendelson R, Shapiro D, Hermann G, et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatric Research 31: 496–502, 1992PubMedGoogle Scholar
  18. Figueroa ML, Rosenbloom BE, Kay AC, et al. A less costly regimen of alglucerase to treat Gaucher’s disease. New England Journal of Medicine 327: 1632–1636, 1992PubMedCrossRefGoogle Scholar
  19. Forster J, Chambers JP, Peters SP, Lee RE, Glew RH. Acute neuropathic Gaucher disease in a black infant. Journal of Pediatrics 93: 823–824, 1978PubMedCrossRefGoogle Scholar
  20. Furbish FS, Oliver KL, Zirzow GC, Brady RO, Barranger JA. Interaction of human placental glucocerebrosidase with hepatic lectins. In Barranger and Brady (Eds). Molecular basis of lysosomal storage disorders, pp.219-232, Academic Press Inc., New York, 1984Google Scholar
  21. Garber AM, Clarke AE, Goldman DP, Gluck ME. Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease. US Congress, Office of Technology Assessment, US Government Printing Office, Washington DC, 1992Google Scholar
  22. Hollak CEM, Aerts JMFG, van Oers MHJ. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1565–1566, 1993PubMedGoogle Scholar
  23. Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, et al. Enzyme replacement therapy in type I Gaucher disease. Transactions of the Association of American Physicians 104: 258–264, 1991PubMedGoogle Scholar
  24. Muguti GI, Nijland A, Gwavava NJT, Nkanza NK. Gaucher’s disease in Zimbabwe. Central African Journal of Medicine 33: 267–269, 1987PubMedGoogle Scholar
  25. Murray GJ, Doebber TW, Shen TY, et al. Targeting of synthetically glycOsylated human placental glucocerebrosidase. Biochemical Medicine 34: 241–246, 1985PubMedCrossRefGoogle Scholar
  26. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty three patients treated for 6 to 24 months. Blood 82: 408–416, 1993PubMedGoogle Scholar
  27. Sato Y, Beutler E, Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. Journal of Clinical Investigation 91: 1909–1917, 1993PubMedCrossRefGoogle Scholar
  28. Williams DN, Bosch D, Boots J, Scheider J. Safety, efficacy, and cost savings in an outpatient intravenous anlibiOlic program. Clinical Therapeutics 15: 169–179, 1993PubMedGoogle Scholar
  29. Zimran A, Hollak CEM, Abrahamov A, van Oers MHJ, Kelly M, et al. Home treatment wilh intravenous enzyme replacement therapy for Gaucher disease: an international collaborative stUdy of 33 patients. Blood 82: 1107–1109, 1993PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 1994

Authors and Affiliations

  • Ernest Beutler
    • 1
  • Alan M. Garber
    • 2
  1. 1.Department of Molecular and Experimental MedicineThe Scripps Research InstituteLa JollaUSA
  2. 2.Palo Alto Department of Veterans Affairs Medical Center and Division of General Internal MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations